Skip to content

Public FDA record

Z-1351-2021: NUVASIVE FREEDOM: End Cap for PRECICE Intramedullary Limb Lengthening System Implant; Packaged End Cap 8

Recall record Z-1351-2021 for Nuvasive Specialized Orthopedics Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1351-2021
Company in FDA record
Nuvasive Specialized Orthopedics Inc
FDA classification date
Apr 5, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Due to not having the full complement of biological assessments for all potential patients and as a result the devices are not indicated for use in individuals under the age of 18 years old.

Source facts

Action
On 02/11/2021, the firm started emailing an "URGENT FIELD SAFETY NOTICE" Notification to customers informing them that due to not having the full complement of biological assessments, the devices are not indicated for use in individuals under the age of 18 years old. Customers are informed to: -An Recalling Firm representative will be contacting your office or you to help with any questions or concerns. -Review, complete, sign and return the attached Consignee Confirmation Form accompanying this notification in accordance with the directions on the form. -If a patient has been previously implanted with a listed device and was under the age of 18, consultation may be warranted, at the discretion of the provider. -If a patient has been previously implanted with a listed device and is pregnant, becomes pregnant, or intends to become pregnant, consultation may be warranted, at the discretion of the provider. -Forward this notice to anyone in your facility that needs to be informed. -Direct any additional manufacturer inquiries to FSNprecice@nuvasive.com -Report to NSO any adverse effect or product complaints related to the use of these devices to FSNprecice@nuvasive.com, whether or not those adverse effects are related to this FSN. As a reminder, the following guidelines according to the Instructions for Use, including, but not limited to: -The IFU should be consulted on an ongoing basis before and throughout patient treatment with Precice products. -These Precice family of devices are contraindicated in patients in which the Precice devices would cross joint spaces or open epiphyseal growth plates. -These Precice family of devices are contraindicated in patients unwilling or incapable of following postoperative care instructions. -Precice System devices should be removed after an implantation period of no more than one year. -Once the physician determines that the Precice/Short/Freedom/Unyte System has achieved its intended use and is no longer requir
Initiated
2021-02-12
Root cause
Device Design
Distribution
Worldwide distribution, including U.S. Nationwide.
Recall number
Z-1351-2021
Recall status
Open, Classified
CDRH record ID
185954
FDA classified
2021-04-05
Recall event number
87353

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗